BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28008661)

  • 1. Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation.
    Ensor CR; Rihtarchik LC; Morrell MR; Hayanga JW; Lichvar AB; Pilewski JM; Wisniewski S; Johnson BA; D'Cunha J; Zeevi A; McDyer JF
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28008661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation.
    Moore CA; Pilewski JM; Venkataramanan R; Robinson KM; Morrell MR; Wisniewski SR; Zeevi A; McDyer JF; Ensor CR
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28273385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation.
    Reams BD; Musselwhite LW; Zaas DW; Steele MP; Garantziotis S; Eu PC; Snyder LD; Curl J; Lin SS; Davis RD; Palmer SM
    Am J Transplant; 2007 Dec; 7(12):2802-8. PubMed ID: 17924993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
    Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
    Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcomes with alemtuzumab induction after lung transplantation.
    Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
    J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
    Sacher VY; Fertel D; Srivastava K; Panos A; Nguyen D; Baxter T; Shafazand S; Pham SM
    Ann Thorac Surg; 2014 Jan; 97(1):268-74. PubMed ID: 24119986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
    Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.
    Glanville AR; Aboyoun CL; Havryk A; Plit M; Rainer S; Malouf MA
    Am J Respir Crit Care Med; 2008 May; 177(9):1033-40. PubMed ID: 18263803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchiolitis obliterans syndrome development in lung transplantation patients.
    Parada MT; Alba A; SepĂșlveda C
    Transplant Proc; 2010; 42(1):331-2. PubMed ID: 20172344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients.
    Martinu T; Howell DN; Davis RD; Steele MP; Palmer SM
    Chest; 2006 Apr; 129(4):1016-23. PubMed ID: 16608952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?
    Burton CM; Iversen M; Mortensen J; Carlsen J; Andersen CB; Milman N; Scheike T
    J Heart Lung Transplant; 2007 Nov; 26(11):1127-34. PubMed ID: 18022078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.
    Kulkarni HS; Cherikh WS; Chambers DC; Garcia VC; Hachem RR; Kreisel D; Puri V; Kozower BD; Byers DE; Witt CA; Alexander-Brett J; Aguilar PR; Tague LK; Furuya Y; Patterson GA; Trulock EP; Yusen RD
    J Heart Lung Transplant; 2019 Jan; 38(1):5-16. PubMed ID: 30391193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Risk of Acute Cellular Rejection in Lung Transplant Recipients with Cystic Fibrosis.
    Calabrese F; Lunardi F; Nannini N; Balestro E; Loy M; Marulli G; Calabrese F; Vuljan SE; Schiavon M; Perissinotto E; Rea F
    Ann Transplant; 2015 Dec; 20():769-76. PubMed ID: 26718747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adherence to home spirometry on bronchiolitis obliterans and graft survival after lung transplantation.
    Kugler C; Fuehner T; Dierich M; DeWall C; Haverich A; Simon A; Welte T; Gottlieb J
    Transplantation; 2009 Jul; 88(1):129-34. PubMed ID: 19584692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.
    Valentine VG; Gupta MR; Walker JE; Seoane L; Bonvillain RW; Lombard GA; Weill D; Dhillon GS
    J Heart Lung Transplant; 2009 Feb; 28(2):163-9. PubMed ID: 19201342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
    Heng D; Sharples LD; McNeil K; Stewart S; Wreghitt T; Wallwork J
    J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of a single episode of minimal acute rejection after lung transplantation.
    Hachem RR; Khalifah AP; Chakinala MM; Yusen RD; Aloush AA; Mohanakumar T; Patterson GA; Trulock EP; Walter MJ
    Transplantation; 2005 Nov; 80(10):1406-13. PubMed ID: 16340783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.
    Glanville AR; Aboyoun C; Klepetko W; Reichenspurner H; Treede H; Verschuuren EA; Boehler A; Benden C; Hopkins P; Corris PA;
    J Heart Lung Transplant; 2015 Jan; 34(1):16-25. PubMed ID: 25049068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The number of FoxP3+ cells in transbronchial lung allograft biopsies does not predict bronchiolitis obliterans syndrome within the first five years after transplantation.
    Krustrup D; Iversen M; Martinussen T; Schultz HH; Andersen CB
    Clin Transplant; 2015 Mar; 29(3):179-84. PubMed ID: 25533723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome.
    Daud SA; Yusen RD; Meyers BF; Chakinala MM; Walter MJ; Aloush AA; Patterson GA; Trulock EP; Hachem RR
    Am J Respir Crit Care Med; 2007 Mar; 175(5):507-13. PubMed ID: 17158279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.